James R. Kasinger
2018
In 2018, James R. Kasinger earned a total compensation of $3.2M as General Counsel at CRISPR Therapeutics AG, a 123% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $197,164 |
|---|---|
| Option Awards | $2,597,975 |
| Salary | $355,985 |
| Other | $9,625 |
| Total | $3,160,749 |
Kasinger received $2.6M in option awards, accounting for 82% of the total pay in 2018.
Kasinger also received $197.2K in non-equity incentive plan, $356K in salary and $9.6K in other compensation.
Rankings
In 2018, James R. Kasinger's compensation ranked 3,655th out of 14,244 executives tracked by ExecPay. In other words, Kasinger earned more than 74.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,655 out of 14,244 | 74th |
Division Manufacturing | 1,353 out of 5,759 | 77th |
Major group Chemicals And Allied Products | 479 out of 2,122 | 77th |
Industry group Drugs | 398 out of 1,811 | 78th |
Industry Biological Products, Except Diagnostic Substances | 85 out of 339 | 75th |
Source: SEC filing on April 30, 2019.
Kasinger's colleagues
We found four more compensation records of executives who worked with James R. Kasinger at CRISPR Therapeutics AG in 2018.
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019